Complete Inhibition of Anisomycin and UV Radiation but Not Cytokine Induced JNK and p38 Activation by an Aryl-substituted Dihydropyrrolopyrazole Quinoline and Mixed Lineage Kinase 7 Small Interfering RNA*

Mixed lineage kinase 7 (MLK7) is a mitogen-activated protein kinase kinase kinase (MAPKKK) that activates the pro-apoptotic signaling pathways p38 and JNK. A library of potential kinase inhibitors was screened, and a series of dihydropyrrolopyrazole quinolines was identified as highly potent inhibitors of MLK7 in vitro catalytic activity. Of this series, an aryl-substituted dihydropyrrolopyrazole quinoline (DHP-2) demonstrated an IC50 of 70 nm for inhibition of pJNK formation in COS-7 cell MLK7/JNK co-transfection assays. In stimulated cells, DHP-2 at 200 nm or MLK7 small interfering RNA completely blocked anisomycin and UV induced but had no effect on interleukin-1β or tumor necrosis factor-α-induced p38 and JNK activation. Additionally, the compound blocked anisomycin and UV-induced apoptosis in COS-7 cells. Heart tissue homogenates from MLK7 transgenic mice treated with DHP-2 at 30 mg/kg had reduced JNK and p38 activation with no apparent effect on ERK activation, demonstrating that this compound can be used to block MLK7-driven MAPK pathway activation in vivo. Taken together, these data demonstrate that MLK7 is the MAPKKK required for modulation of the stress-activated MAPKs downstream of anisomycin and UV stimulation and that DHP-2 can be used to block MLK7 pathway activation in cells as well as in vivo.

[1]  E. Tosti,et al.  The Stress Kinase MRK Contributes to Regulation of DNA Damage Checkpoints through a p38γ-independent Pathway* , 2004, Journal of Biological Chemistry.

[2]  H. Krum,et al.  p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. , 2004, Journal of the American College of Cardiology.

[3]  P. Iversen,et al.  Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation. , 2004, Journal of molecular and cellular cardiology.

[4]  J. Kyriakis,et al.  MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation , 2004, Nature Cell Biology.

[5]  R. Campbell,et al.  Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. , 2004, Bioorganic & medicinal chemistry letters.

[6]  Yong-Yeon Cho,et al.  A Novel Role for Mixed-Lineage Kinase-Like Mitogen-Activated Protein Triple Kinase α in Neoplastic Cell Transformation and Tumor Development , 2004, Cancer Research.

[7]  Eugene M. Johnson,et al.  Mixed-lineage kinases: a target for the prevention of neurodegeneration. , 2004, Annual review of pharmacology and toxicology.

[8]  A. Alonso,et al.  Multiple independent kinase cascades are targeted by hyperosmotic stress but only one activates stress kinase p38. , 2004, Experimental cell research.

[9]  Xiaohong Yu,et al.  Effect of C-terminal truncations on MLK7 catalytic activity and JNK activation. , 2003, Biochemical and biophysical research communications.

[10]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[11]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[12]  A. Clerk,et al.  Kinases as therapeutic targets for heart failure , 2003, Nature Reviews Drug Discovery.

[13]  J. Yang,et al.  A novel zinc finger protein, ZZaPK, interacts with ZAK and stimulates the ZAK-expressing cells re-entering the cell cycle. , 2003, Biochemical and biophysical research communications.

[14]  J. Saffitz,et al.  c-Jun N-Terminal Kinase Activation Mediates Downregulation of Connexin43 in Cardiomyocytes , 2002, Circulation research.

[15]  Jaw‐Ji Yang.  Mixed lineage kinase ZAK utilizing MKK7 and not MKK4 to activate the c-Jun N-terminal kinase and playing a role in the cell arrest. , 2002, Biochemical and biophysical research communications.

[16]  R. Ruggieri,et al.  MRK, a Mixed Lineage Kinase-related Molecule That Plays a Role in γ-Radiation-induced Cell Cycle Arrest* , 2002, The Journal of Biological Chemistry.

[17]  Heping Cheng,et al.  p38 Mitogen-Activated Protein Kinase Mediates a Negative Inotropic Effect in Cardiac Myocytes , 2002, Circulation research.

[18]  D. Bozyczko‐Coyne,et al.  Mixed lineage kinase activity of indolocarbazole analogues. , 2002, Bioorganic & medicinal chemistry letters.

[19]  D. Kass,et al.  The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Beavis,et al.  Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase. , 2001, Journal of molecular and cellular cardiology.

[21]  L. Greene,et al.  CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family* , 2001, The Journal of Biological Chemistry.

[22]  Y. Wang.  Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach. , 2001, Current opinion in pharmacology.

[23]  E. Nishida,et al.  Identification and Characterization of a Novel MAP Kinase Kinase Kinase, MLTK* , 2001, The Journal of Biological Chemistry.

[24]  R. Lefkowitz,et al.  β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3 , 2000 .

[25]  R. Scott,et al.  MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo , 2000, Journal of neurochemistry.

[26]  T. C. Liu,et al.  Cloning and expression of ZAK, a mixed lineage kinase-like protein containing a leucine-zipper and a sterile-alpha motif. , 2000, Biochemical and biophysical research communications.

[27]  D. Bar-Sagi,et al.  Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. , 2000, Science.

[28]  Roger J. Davis,et al.  The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins , 1999, Molecular and Cellular Biology.

[29]  J. Guerrero,et al.  Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. , 1999, The Journal of clinical investigation.

[30]  R. Hajjar,et al.  Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. , 1998, The Journal of clinical investigation.

[31]  A. Maroney,et al.  Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. , 2002, Progress in medicinal chemistry.

[32]  G. Kucera,et al.  c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. , 2002, Leukemia research.

[33]  G. Johnson,et al.  Signalling: Mixed-lineage kinase control of JNK and p38 MAPK pathways , 2002, Nature Reviews Molecular Cell Biology.